Recombinant human Transforming Growth Factor Beta-1 (TGF beta-1) protein (GF-230)

$300.00


Human Transforming Growth Factor beta1 (TGF- beta1 ) is stimulatory for cells of mesenchymal origin and inhibitory for cells of epithelial or neuroectodermal origin. Mature TGF- beta1 is a disulfide-linked homodimer of two chains composed of 112 amino acid residues each. There is a 70% homology between human TGF- beta1 and human TGF- beta2. Human TGF- beta1 is produced in genetically engineered bacteria, and purified by sequential chromatography. This recombinant protein has a size of 25 kDa (dimeric protein).
Alternative names CED, DPD1, LAP, Latency-associated peptide, Prepro transforming growth factor beta 1, TGF beta, TGF beta 1, TGF beta 1 protein, TGF-beta 1 protein, TGF-beta-1, TGF-beta-5, TGF-beta1, TGFB, Tgfb-1, tgfb1, TGFB1_HUMAN, TGFbeta, TGFbeta1, Transforming Growth Factor b1, Transforming Growth Factor beta 1, Transforming growth factor beta 1a, transforming growth factor beta-1, transforming growth factor, beta 1
Type Recombinant.
Source E. coli


Description

Product name Recombinant human Transforming Growth Factor Beta-1 (TGF beta-1) protein (GF-230)
Catalog number GF-230-2
Brand family Austral Biologicals
Product type Proteins and Peptides


Biological Information

Purity Over 98% (non-reduced SDS gel electrophoresis)
Concentration 0.2 mg/ml
Purification method Purified by sequential chromatography


Target

SwissProt ID Link P01137
Gene Aliases TGFB1, TGFB
Function Multifunctional protein that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It positively and negatively regulates many other growth factors. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. Can promote either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. At high concentrations, leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression, favoring Treg cell development. At low concentrations in concert with IL-6 and IL-21, leads to expression of the IL-17 and IL-23 receptors, favoring differentiation to Th17 cells. Mediates SMAD2/3 activation by inducing its phosphorylation and subsequent translocation to the nucleus. Can induce epithelial-to-mesenchymal transition (EMT) and cell migration in various cell types
Subcellular Location Secreted › extracellular space › extracellular matrix
Involvement in Disease The disease is caused by mutations affecting the gene. An autosomal dominant disorder characterized by hyperostosis and sclerosis of the diaphyses of long bones. The disease typically presents in early childhood with pain, muscular weakness and waddling gait, and in some cases other features such as exophthalmos, facial paralysis, hearing difficulties and loss of vision
Post-Translational Modification Glycosylated. The precursor is cleaved into mature TGF-beta-1 and LAP, which remains non-covalently linked to mature TGF-beta-1 rendering it inactive
Tissue Specificity Highly expressed in bone. Abundantly expressed in articular cartilage and chondrocytes and is increased in osteoarthritis (OA). Colocalizes with ASPN in chondrocytes within OA lesions of articular cartilage
Subunit Structure Homodimer; disulfide-linked, or heterodimer with TGFB2 (By similarity). Secreted and stored as a biologically inactive form in the extracellular matrix in a 290 kDa complex (large latent TGF-beta1 complex) containing the TGFB1 homodimer, the latency-associated peptide (LAP), and the latent TGFB1 binding protein-1 (LTBP1). The complex without LTBP1 is known as the'small latent TGF-beta1 complex'. Dissociation of the TGFB1 from LAP is required for growth factor activation and biological activity. Release of the large latent TGF-beta1 complex from the extracellular matrix is carried out by the matrix metalloproteinase MMP3 (By similarity). May interact with THSD4; this interaction may lead to sequestration by FBN1 microfibril assembly and attenuation of TGFB signaling. Interacts with the serine proteases, HTRA1 and HTRA3: the interaction with either inhibits TGFB1-mediated signaling. The HTRA protease activity is required for this inhibition (By similarity). Latency-associated peptide interacts with NREP; the interaction results in a decrease in TGFB1 autoinduction (By similarity). Interacts with CD109, DPT and ASPN
Sequence Similarities Belongs to the TGF-beta family


Poduct Presentation

Form 25 µl (0.20 mg/ml) in 5 mM HCl (pH 2.5). Some of the liquid in the vial could have been evaporated with changes in the final volume. However, the 5 µg of the protein are still inside the vial. We recommend, in order to control the proper concentration, to dilute the entire content to a known volume with 5 mM HCl. Do not freeze this material


Storage and Shipping Information

Storage Store at +4 ºC


References and Citations

Citations 1. Ichijo, H. et al.(1994) The Journal of Biological Chemistry, Vol 266, No. 33, May, 22459-22464.
2. Yan, Z., Winawer, S., and Friedman, E., (1994) The Journal of Biological Chemistry, Vol 269, No. 18, May, 13231-13237